RUNX1/ETO-IN-1

Overview

RUNX1/ETO-IN-1 is a RUNX1-ETO oncogenic fusion protein inhibitor that specifically targets the NHR2 oligomerization domain. RUNX1/ETO-IN-1 directly interacts with the NHR2 ( K D,app = 39 μM). RUNX1/ETO-IN-1 exhibits anti-leukemic activity by inducing apoptosis and promoting differentiation in RUNX1/ETO-translocated AML cells. RUNX1/ETO-IN-1 remains essentially uncharged at physiological pH, demonstrating superior membrane permeability.

Application

Products | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > RUNX | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-174367
• CAS No.: 923865-06-9
• Molecular Formula: C21H25N3O3S
• Molecular Weight: 399.51
• Purity: 91.18%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source